Advancing a new generation of treatments for central nervous system disorders

Latest News

Sign up for our RSS Feed.
21 May 2014 NeurOp Selects NP10679 as Development Candidate for SAH Read More
11 Apr 2014 NeurOp Receives Third Year of NIH Funding for Ischemia Research Read More
15 Apr 2013 NeurOp Receives Second Half of NIH Grant for Meeting Schizophrenia Research Mile ... Read More

NeurOp, Inc. is a biopharmaceutical company developing new medicines to treat central nervous system disorders, including major depression, neuropathic pain and ischemia. Our mission is to develop a new generation of N-methyl-D-aspartate (NMDA) receptor blockers, which inhibit proteins that play an important role in neuron signaling. Our compounds specifically target the NR2B subtype of these receptors offering an unprecedented opportunity to improve the safety and tolerability of this therapeutic class without compromising efficacy.

Learn more about our science.